JP2023516685A5 - - Google Patents

Info

Publication number
JP2023516685A5
JP2023516685A5 JP2022552807A JP2022552807A JP2023516685A5 JP 2023516685 A5 JP2023516685 A5 JP 2023516685A5 JP 2022552807 A JP2022552807 A JP 2022552807A JP 2022552807 A JP2022552807 A JP 2022552807A JP 2023516685 A5 JP2023516685 A5 JP 2023516685A5
Authority
JP
Japan
Prior art keywords
seq
viral vector
vector according
promoter
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022552807A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023516685A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/020721 external-priority patent/WO2021178571A1/en
Publication of JP2023516685A publication Critical patent/JP2023516685A/ja
Publication of JP2023516685A5 publication Critical patent/JP2023516685A5/ja
Pending legal-status Critical Current

Links

JP2022552807A 2020-03-03 2021-03-03 Hivを処置するためのリンパ球における外因性因子のオンデマンド発現 Pending JP2023516685A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062984716P 2020-03-03 2020-03-03
US62/984,716 2020-03-03
PCT/US2021/020721 WO2021178571A1 (en) 2020-03-03 2021-03-03 On demand expression of exogenous factors in lymphocytes to treat hiv

Publications (2)

Publication Number Publication Date
JP2023516685A JP2023516685A (ja) 2023-04-20
JP2023516685A5 true JP2023516685A5 (cg-RX-API-DMAC7.html) 2024-03-04

Family

ID=77614437

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022552807A Pending JP2023516685A (ja) 2020-03-03 2021-03-03 Hivを処置するためのリンパ球における外因性因子のオンデマンド発現

Country Status (10)

Country Link
US (2) US20240279678A1 (cg-RX-API-DMAC7.html)
EP (1) EP4114439A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023516685A (cg-RX-API-DMAC7.html)
KR (1) KR20220150320A (cg-RX-API-DMAC7.html)
CN (1) CN115551532A (cg-RX-API-DMAC7.html)
AU (1) AU2021232603A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022017678A2 (cg-RX-API-DMAC7.html)
CA (1) CA3170630A1 (cg-RX-API-DMAC7.html)
IL (1) IL296096A (cg-RX-API-DMAC7.html)
WO (1) WO2021178571A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL297238B2 (en) 2016-01-15 2024-08-01 American Gene Tech Int Inc Methods and preparations for gamma-delta T-cell activation
ES2911448T3 (es) 2016-03-09 2022-05-19 American Gene Tech Int Inc Vectores combinados y métodos para el tratamiento del cáncer
US12559769B2 (en) 2017-06-16 2026-02-24 American Gene Technologies International Inc. Methods and compositions for the activation of tumor cytotoxicity via human gamma-delta t-cells
EP3876952A4 (en) 2018-11-05 2022-08-24 American Gene Technologies International Inc. VECTOR SYSTEM FOR EXPRESSING REGULATORY RNA
US20230140346A1 (en) * 2020-05-19 2023-05-04 Ixaka France Promoter Sequences for In Vitro and In Vivo Expression of Gene Therapy Products in CD3+ Cells

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4645697A (en) * 1996-09-11 1998-04-02 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Aav4 vector and uses thereof
US7368114B2 (en) * 2001-10-25 2008-05-06 The United States Of America As Represented By The Department Of Health And Human Services Fusion protein including of CD4
US7811580B2 (en) * 2002-05-07 2010-10-12 Novartis Vaccines & Diagnostics, Inc. Chimeric HIV Env proteins comprising CD4 mini-proteins or CD4 mimetics that are capable of inducing neutralizing antibody responses against cryptic Env epitopes
US9719106B2 (en) * 2013-04-29 2017-08-01 The Trustees Of The University Of Pennsylvania Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
JP6991131B2 (ja) * 2015-09-22 2022-02-03 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Hiv感染症を処置するためにt細胞を再度方向付ける方法
WO2017213697A1 (en) * 2016-06-08 2017-12-14 American Gene Technologies International Inc. Non-integrating viral delivery system and methods related thereto
CA3028982A1 (en) * 2016-07-08 2018-01-11 American Gene Technologies International Inc. Hiv pre-immunization and immunotherapy
KR20230093381A (ko) * 2017-01-09 2023-06-27 아메리칸 진 테크놀로지스 인터내셔널 인코포레이티드 예비-면역화 단계가 없는 hiv 면역요법
US12559769B2 (en) * 2017-06-16 2026-02-24 American Gene Technologies International Inc. Methods and compositions for the activation of tumor cytotoxicity via human gamma-delta t-cells
EP3773622A4 (en) * 2018-03-27 2021-12-01 American Gene Technologies International Inc. METHODS OF PREPARING GENETICALLY MODIFIED LYMPHOCYTES
KR20210031898A (ko) * 2018-07-13 2021-03-23 난징 레전드 바이오테크 씨오., 엘티디. 전염병을 치료하기 위한 공동수용체 시스템

Similar Documents

Publication Publication Date Title
US11612649B2 (en) HIV pre-immunization and immunotherapy
Bunnell et al. Gene therapy for infectious diseases
US20250121050A1 (en) Methods of producing cells resistant to hiv infection
CN110462029B (zh) 无预先免疫步骤的hiv免疫疗法
JP2019527055A5 (cg-RX-API-DMAC7.html)
US20240115604A1 (en) Methods of manufacturing genetically-modified lymphocytes
US20240141374A1 (en) On demand expression of exogenous factors in lymphocytes
von Gegerfelt et al. Long-lasting decrease in viremia in macaques chronically infected with simian immunodeficiency virus SIVmac251 after therapeutic DNA immunization
Buffa et al. A single administration of lentiviral vectors expressing either full-length human immunodeficiency virus 1 (HIV-1) HXB2 Rev/Env or codon-optimized HIV-1JR-FL gp120 generates durable immune responses in mice
Lori et al. Gene therapy approaches to HIV infection
RU2697781C2 (ru) Вспомогательный плазмидный лентивирусный экспрессионный вектор для получения высоких титров vpx-содержащих лентивирусных частиц, обеспечивающий эффективное заражение моноцитов и дендритных клеток человека
Moriya et al. Abrogation of AIDS vaccine-induced cytotoxic T-lymphocyte efficacy in vivo due to a change in viral epitope flanking sequences
Warner et al. Human immunodeficiency virus immunotherapy using a retroviral vector
WO2025064901A2 (en) Hiv vaccination and immunotherapy
Fujii et al. A potential live vector, foamy virus, directed intra-cellular expression of ovine interferon-τ exhibited the resistance to HIV infection
WO2025050047A1 (en) Combination immunotherapy and antiviral treatment